Payment overview · 2025
General Payments
$256.33
8 reported records · 5 companies
Healthcare provider profile · identity verified
Ryan Mark Truxillo, MD
Allopathic & Osteopathic Physicians|Family Medicine · CHALMETTE, LA · NPI 1093754939
Verified facts
What the public records show
CMS Open Payments records show Ryan Mark Truxillo, MD received $256.33 in general payments during 2025 across 8 reported records.
Lilly USA, LLC accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $97.44 | 38.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.57 | 27.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $40.28 | 15.7% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.76 | 9.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $24.28 | 9.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $256.33 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $97.44 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $69.57 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $40.28 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.76 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 95 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
95 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
89 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 742 | 246 |
| Amlodipine Besylate | Amlodipine Besylate | 648 | 222 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 605 | 192 |
| Pantoprazole Sodium | Pantoprazole Sodium | 455 | 130 |
| Gabapentin | Gabapentin | 444 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 432 | 130 |
| Trazodone Hcl | Trazodone Hcl | 367 | 108 |
| Losartan Potassium | Losartan Potassium | 360 | 114 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 321 | 110 |
| Lisinopril | Lisinopril | 295 | 95 |
| Escitalopram Oxalate | Escitalopram Oxalate | 290 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 277 | 95 |
| Omeprazole | Omeprazole | 259 | 73 |
| Metformin Hcl | Metformin Hcl | 239 | 72 |
| Alprazolam | Alprazolam | 223 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 220 | 72 |
| Alendronate Sodium | Alendronate Sodium | 215 | 71 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 199 | 28 |
| Lorazepam | Lorazepam | 192 | 46 |
| Tramadol Hcl | Tramadol Hcl | 191 | 50 |
| Ozempic | Semaglutide | 188 | 42 |
| Metformin Hcl Er | Metformin Hcl | 177 | 57 |
| Eliquis | Apixaban | 176 | 44 |
| Glipizide Er | Glipizide | 172 | 54 |
| Clonazepam | Clonazepam | 169 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 167 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 162 | 60 |
| Sertraline Hcl | Sertraline Hcl | 157 | 45 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 45 |
| Carvedilol | Carvedilol | 153 | 50 |
| Furosemide | Furosemide | 146 | 45 |
| Meloxicam | Meloxicam | 145 | 60 |
| Tizanidine Hcl | Tizanidine Hcl | 145 | 57 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 144 | 40 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 133 | 23 |
| Ondansetron Odt | Ondansetron | 126 | 38 |
| Potassium Chloride | Potassium Chloride | 123 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 122 | 42 |
| Montelukast Sodium | Montelukast Sodium | 119 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 116 | 38 |
| Famotidine | Famotidine | 112 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 109 | 51 |
| Zolpidem Tartrate | Zolpidem Tartrate | 106 | 19 |
| Allopurinol | Allopurinol | 98 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 29 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 96 | 30 |
| Farxiga | Dapagliflozin Propanediol | 95 | 24 |
| Jardiance | Empagliflozin | 89 | 24 |
| Simvastatin | Simvastatin | 85 | 25 |
| Ezetimibe | Ezetimibe | 83 | 24 |
| Promethazine Hcl | Promethazine Hcl | 81 | 13 |
| Diazepam | Diazepam | 78 | 18 |
| Meclizine Hcl | Meclizine Hcl | 77 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 21 |
| Pregabalin | Pregabalin | 70 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | 18 |
| Donepezil Hcl | Donepezil Hcl | 69 | 20 |
| Buspirone Hcl | Buspirone Hcl | 68 | 20 |
| Irbesartan | Irbesartan | 68 | 21 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 15 |
| Ibuprofen | Ibuprofen | 65 | 24 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 65 | 14 |
| Eszopiclone | Eszopiclone | 61 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 60 | 16 |
| Prednisone | Prednisone | 60 | 52 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 14 |
| Finasteride | Finasteride | 52 | 18 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 51 | 18 |
| Linzess | Linaclotide | 49 | 14 |
| Xarelto | Rivaroxaban | 49 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 12 |
| Azelastine Hcl | Azelastine Hcl | 45 | 17 |
| Celecoxib | Celecoxib | 45 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 40 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 39 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 11 |
| Bupropion Xl | Bupropion Hcl | 38 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 11 |
| Naproxen | Naproxen | 37 | 14 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 37 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 12 |
| Glipizide | Glipizide | 35 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 35 | 13 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 34 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 33 | 30 |
| Doxepin Hcl | Doxepin Hcl | 33 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Nifedipine Er | Nifedipine | 32 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Atenolol | Atenolol | 31 | 11 |
| Baclofen | Baclofen | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Nystatin | Nystatin | 29 | 14 |
| Spironolactone | Spironolactone | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 27 | suppressed |
| Azithromycin | Azithromycin | 27 | 24 |
| Chlorthalidone | Chlorthalidone | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 26 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Methocarbamol | Methocarbamol | 25 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Invokana | Canagliflozin | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 17 | suppressed |
| Cilostazol | Cilostazol | 16 | suppressed |
| Entresto | Sacubitril/Valsartan | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $256.33 · 8 records | Lilly USA, LLC | Dexcom G6 Transmitter, FARXIGA, Kerendia, MOUNJARO, The Cologuard Plus Collection Kit | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error